10 studies found for:    ABT-874
Show Display Options
Rank Status Study
1 Terminated Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease
Condition: Crohn's Disease
Interventions: Biological: Placebo;   Biological: ABT-874
2 Completed Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Condition: Psoriasis
Interventions: Drug: Anti IL-12 monoclonal antibody/ABT-874;   Drug: placebo
3 Completed Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS)
Condition: Multiple Sclerosis
Interventions: Drug: ABT-874/Human monoclonal antibody against IL-12;   Drug: Placebo
4 Completed A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Condition: Plaque Psoriasis
Interventions: Drug: Placebo;   Biological: ABT-874
5 Completed A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis
Condition: Psoriasis
Interventions: Drug: ABT-874;   Drug: Methotrexate
6 Completed Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Condition: Moderate to Severe Plaque Psoriasis
Interventions: Biological: ABT-874;   Biological: etanercept;   Drug: placebo
7 Completed Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Condition: Plaque Psoriasis
Interventions: Biological: ABT-874;   Biological: etanercept;   Drug: placebo
8 Completed Phase 1 BA Study, Single Center With Healthy Volunteers
Condition: Healthy
Intervention: Drug: ABT-874
9 Completed Open Label Continuation Study in Moderate to Severe Psoriasis
Condition: Moderate to Severe Plaque Psoriasis
Intervention: Drug: ABT-874
10 Withdrawn Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Substrates.
Condition: Moderate to Severe Plaque Psoriasis
Intervention: Drug: briakinumab

Indicates status has not been verified in more than two years